The prevalence of HIV resistance mutations and their influence on the shedding of HIV-1 into peritoneal dialysis effluent

被引:1
作者
Mooko, Teboho [1 ,2 ,3 ]
Bisiwe, Feziwe Busiswa [1 ,4 ]
Chikobvu, Perpertual [5 ,6 ]
Morobadi, Molefi Daniel [3 ,7 ]
Mofokeng, Thabiso Rafaki Petrus [1 ,5 ]
Nyaga, Martin Munene [2 ,3 ]
Kemp, Gabre [8 ]
Goedhals, Dominique [3 ,9 ]
Ndlovu, Kwazi Celani Zwakele [10 ,11 ]
机构
[1] Univ Free State, Dept Internal Med, Bloemfontein, South Africa
[2] Univ Free State, Next Generat Sequencing Unit, Bloemfontein, South Africa
[3] Univ Free State, Div Virol, Bloemfontein, South Africa
[4] Univ Free State, Div Nephrol, Bloemfontein, South Africa
[5] Dept Hlth Free State, Bloemfontein, South Africa
[6] Univ Free State, Dept Community Hlth, Bloemfontein, South Africa
[7] Ampath Labs, Pretoria, South Africa
[8] Univ Free State, Dept Microbiol & Biochem, Bloemfontein, South Africa
[9] PathCare Vermaak, Pretoria, South Africa
[10] Univ Cape Town, Kidney & Hypertens Res Unit, Cape Town, South Africa
[11] Univ Cape Town, Div Nephrol & hypertens, Rondebosch, South Africa
基金
新加坡国家研究基金会;
关键词
antiretroviral therapy; end-stage kidney failure; HIV mutations; HIV shedding; peritoneal dialysis; HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE; ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; ADHERENCE; RISK;
D O I
10.1002/jmv.29734
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV drug resistance mutations (HIVDRMs) are important determinants of therapeutic effects and outcomes even in end-stage kidney failure (ESKF) people living with HIV (PLWHIV). This study evaluated the prevalence of HIVDRMs and their effect on the shedding of HIV-1 into peritoneal dialysis (PD) effluents. This cross-sectional study of PLWHIV and having ESKF and managed with antiretroviral therapy (ART) and PD, collected enrolled patients' demographic information, clinical and laboratory data, and sequenced HIV-1 RNA in unsuppressed plasma and PD effluent samples. HIV viral load and HIVDRMs were determined using qualitative polymerase chain reaction (qPCR) and Stanford University HIVDRM Database, respectively. There were 60 participants recruited with a median age of 43.0 (interquartile range [IQR], 38.0-47) years and were predominantly on abacavir (88.3%), lamivudine (98.3%), and efavirenz (70%) for a median duration of 8 (IQR, 5-11) years. Among participants with detectable HIV-1 in PD effluents, the prevalence of HIVDRMs was 62.5% (5/8) compared to 7.7% (4/52) among those with undetectable HIV-1 (p = 0.001) with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations predominating. On Spearman's correlation analysis, high plasma HIV levels (rho = 0.649, p < 0.001), T-cell CD4 count (rho = -0370, p < 0.004), serum creatinine (rho = -0.396, p < 0.002), and white blood cell count (rho = -0.294, p < 0.023) levels were significant factors correlated with the detection of HIV-1 in PD effluents. Moreover, HIVDRMs presence (rho = 0.504, p < 0.001) particularly NNRTI resistance (rho = 0.504, p < 0.001) were also significantly correlated with detection of HIV-1 in PD effluents. The presence of HIVDRMs, high plasma HIV viral load, and T-cell CD4 count were correlated with HIV-1 shedding into PD effluents.
引用
收藏
页数:10
相关论文
共 32 条
[1]   Race, Kidney Disease Progression, and Mortality Risk in HIV-Infected Persons [J].
Alves, Tahira P. ;
Hulgan, Todd ;
Wu, Pingsheng ;
Sterling, Timothy R. ;
Stinnette, Samuel E. ;
Rebeiro, Peter F. ;
Vincz, Andrew J. ;
Bruce, Marino ;
Ikizler, T. Alp .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (12) :2269-2275
[2]  
[Anonymous], 2016, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach
[3]   HIV and kidney diseases: 35 years of history and consequences [J].
Campos, Pedro ;
Ortiz, Alberto ;
Soto, Karina .
CLINICAL KIDNEY JOURNAL, 2016, 9 (06) :772-781
[4]   The impact of HIV on chronic kidney disease outcomes [J].
Choi, A. I. ;
Rodriguez, R. A. ;
Bacchetti, P. ;
Bertenthal, D. ;
Volberding, P. A. ;
O'Hare, A. M. .
KIDNEY INTERNATIONAL, 2007, 72 (11) :1380-1387
[5]  
EACS. European AIDS Clinical Society, European guidelines for treatment of HIV infected adults in Europe
[6]   High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa [J].
Etta, Elizabeth M. ;
Mavhandu, Lufuno ;
Manhaeve, Cecile ;
McGonigle, Keanan ;
Jackson, Patrick ;
Rekosh, David ;
Hammarskjold, Marie-Louise ;
Bessong, Pascal O. ;
Tebit, Denis M. .
AIDS RESEARCH AND THERAPY, 2017, 14
[7]   HIV-related nephropathy: A South African perspective [J].
Gerntholtz, TE ;
Goetsch, SJW ;
Katz, I .
KIDNEY INTERNATIONAL, 2006, 69 (10) :1885-1891
[8]   Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets [J].
Gisslen, M. ;
Svedhem, V. ;
Lindborg, L. ;
Flamholc, L. ;
Norrgren, H. ;
Wendahl, S. ;
Axelsson, M. ;
Sonnerborg, A. .
HIV MEDICINE, 2017, 18 (04) :305-307
[9]   Antiretroviral Treatment Interruptions Predict Female Genital Shedding of Genotypically Resistant HIV-1 RNA [J].
Graham, Susan M. ;
Jalalian-Lechak, Zahra ;
Shafi, Juma ;
Chohan, Vrasha ;
Deya, Ruth W. ;
Jaoko, Walter ;
Mandaliya, Kishor N. ;
Peshu, Norbert M. ;
Overbaugh, Julie ;
McClelland, R. Scott .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (05) :511-518
[10]   Antiretroviral Adherence and Development of Drug Resistance Are the Strongest Predictors of Genital HIV-1 Shedding among Women Initiating Treatment [J].
Graham, Susan M. ;
Masese, Linnet ;
Gitau, Ruth ;
Jalalian-Lechak, Zahra ;
Richardson, Barbra A. ;
Peshu, Norbert ;
Mandaliya, Kishor ;
Kiarie, James N. ;
Jaoko, Walter ;
Ndinya-Achola, Jeckoniah ;
Overbaugh, Julie ;
McClelland, R. Scott .
JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (10) :1538-1542